Want to see LLY full AI Analyst Report?
Operating Expense Breakdown
Details spending on R&D, selling/general/admin and manufacturing to show how Lilly allocates cash between developing new drugs and running its commercial operations. Highlights whether the company is investing for long‑term growth, where cost pressure may hit margins, and how efficiently management turns spending into revenue.Lilly is deliberately ratcheting up recurring R&D and marketing/S&A to fund massive new product launches, international rollouts and manufacturing scale, while large, episodic acquired IPR&D and impairment items from aggressive M&A create pronounced lumpiness. Management absorbed hefty IPR&D charges in Q2 yet still raised guidance thanks to strong top‑line leverage, so current spend is driving durable growth but also earnings volatility; watch future IPR&D/impairment timing and MS&A cadence to judge whether margin gains persist as launch noise, pricing pressure and H2 seasonality normalize.
Date | Research and Development | Marketing, Selling, and Administrative | Acquired In-Process Research and Development | Impairment, Restructuring, and Other |
|---|---|---|---|---|
Jun 30, 2026 | $3.82B | $3.43B | $2.78B | $703.00M |
Mar 31, 2026 | $3.51B | $2.93B | $584.00M | $279.00M |
Dec 31, 2025 | $3.80B | $3.13B | $528.80M | $84.10M |
Sep 30, 2025 | $3.47B | $2.74B | $655.70M | $364.90M |
Jun 30, 2025 | $3.34B | $2.75B | $153.80M | $0.00 |
Mar 31, 2025 | $2.73B | $2.47B | $1.57B | $35.00M |
Dec 31, 2024 | $3.02B | $2.42B | $189.20M | $344.00M |
Sep 30, 2024 | $2.73B | $2.10B | $2.83B | $81.60M |
Jun 30, 2024 | $2.71B | $2.12B | $154.30M | $435.00M |
Mar 31, 2024 | $2.52B | $1.95B | $110.50M | $0.00 |